In order to stimulate excellent research, the "Southern Norway Regional Health Authority" ("Helse Sør RHF") rewards outstanding publications every half-year. A paper with Fang Liu from Eivind Hovig's group as first author was chosen as one of the two winners in the category "basic research" for the second part of 2006.
The article, entitled "A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies", was published in the July issue of top rated journal "Nature Biotechnology" (impact factor 22,7).
Below is a summary of the findings, written by Fang Liu, as well as information about the bioinformatics group and about Fang Liu herself, written by Eivind Hovig.
Recent publications
From major journals, first or last author from the Institute for Cancer Research
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900
Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH(2022) Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma Front Oncol, 12, 873532 DOI 10.3389/fonc.2022.873532, PubMed 35574381
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich Det al.(2022) Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway J Transl Med, 20(1), 225 DOI 10.1186/s12967-022-03432-5, PubMed 35568909